CLAIMS

1. Peptide analogs of nociceptin having general formula (I) :

Phe^{1}-Ψ-Gly^{2}-Gly^{3}-**Xaa^{4}**-Thr^{5}-Gly^{6}-Ala^{7}-Arg^{8}-Lys^{9}-Ser^{10}-Ala^{11}-Arg^{12}-Lys^{13}-**Xbb^{14}-Xcc^{15}**-Asn^{16}-Gln^{17}-**R**

(I)

wherein

Ψ represents the bond between the first two aminoacidic residues and is selected from CO-NH and CH_2-NH; **Xaa^{4}** is selected from pXPhe where "X" represents H,Cl, Br, I, F, NO_2, CN and "p" indicates the para- position of the phenyl ring of Phe, Tic, Phg, Atc, Aic, which represent tetrahydroisochinolin-3-carboxylic acid, phenylglicin, aminotetralincarboxylic acid, aminoindancarboxylic acid, respectively; **Xbb^{14}** is selected from Trp, Arg, Lys, Leu, Orn, homoArg, diaminobutyric acid, diaminopropionic acid; **Xcc^{15}** is selected from Phe, Arg, Lys, Ala, Orn or Trp; **R** represents a terminal amide group (-NH_2) or a terminal carboxy group (-OH); wherein the aminoacidic residues or derivatives thereof can be in D or L configuration; and pharmaceutically acceptable salts thereof.

2. Peptide according to Claim 1, wherein Ψ is CO-NH or CH_2-NH; **Xaa^{4}** is Phe, pClPhe, pBrPhe, pIPhe, PNO_2Phe or pCNPhe; **Xbb^{14}** is Arg, Lys, Leu, Orn; **Xcc^{15}** is Arg, -Lys, Ala, Orn or Trp, **R** is –NH_2 or –OH.

3. Peptide according to Claim 2, wherein Ψ is CO-NH or CH_2-NH; **Xaa^{4}** is L-pFPhe or L-PNO_2Phe; **Xbb^{14}** is L-Arg, L-Lys, or L-Leu; **Xcc^{15}** is L-Arg, L-Lys or L-Ala; **R** is –NH_2.

4. Peptide according to Claim 3, selected from the group consisting of:

Ψ is CO-NH; Xaa^{4} is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Lys; R is NH_2

Ψ is CH_2-NH; Xaa^{4} is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Lys; R is NH_2

Ψ is CO-NH; Xaa^{4} is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Lys; R is OH

V. Ψ is CH_2-NH; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Lys; R is OH

VI. Ψ is CO-NH; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Arg; R is NH_2

VII. Ψ is CH_2-NH; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Arg; R is NH_2

Ψ is CO-NH; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Arg; R is OH

Ψ is CH_2-NH; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Arg; R is OH

Ψ is CO-NH; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is D-Lys; R is NH_2

Ψ is CH_2-NH; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is D-Lys; R is NH_2

Ψ is CO-NH; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is D-Lys; R is OH

Ψ is CH_2-NH; Xaa^4 is Phe(pF); Xbb^{14} is Arg; Xcc^{15} is D-Lys; R is OH

Ψ is CO-NH; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is Lys; R is NH_2

Ψ is CH_2-NH; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is Lys; R is NH_2

Ψ is CO-NH; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is Lys; R is OH

Ψ is CH_2-NH; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is Lys; R is OH

Ψ is CO-NH; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is D-Lys; R is NH_2

Ψ is CH_2-NH; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is D-Lys; R is NH_2

Ψ is CO-NH; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is D-Lys; R is OH

VIII. Ψ is CH_2-NH; Xaa^4 is Phe(pF); Xbb^{14} is D-Arg; Xcc^{15} is D-Lys; R is OH

IX. Ψ is CO-NH; Xaa^4 is D-Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Lys; R is NH_2

X. Ψ is CH_2-NH; Xaa^4 is D-Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Lys; R is NH_2

Ψ is CO-NH; Xaa^4 is D-Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Lys; R is OH

Ψ is CH_2-NH; Xaa^4 is D-Phe(pF); Xbb^{14} is Arg; Xcc^{15} is Lys; R is OH

Ψ is CO-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is Lys; R is NH_2

Ψ is CH_2-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is Lys; R is NH_2

Ψ is CO-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is Lys; R is OH

Ψ is CH_2-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is Lys; R is OH

Ψ is CO-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is Arg; R is NH_2

Ψ is CH_2-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is Arg; R is NH_2

XI. Ψ is CO-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is Arg; R is OH

Ψ is CH_2-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is Arg; R is OH

Ψ is CO-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is D-Lys; R is NH_2

Ψ is CH_2-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is D-Lys; R is NH_2

Ψ is CO-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is D-Lys; R is OH

Ψ is CH_2-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is D-Lys; R is OH

Ψ is CO-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is D-Arg; Xcc^{15} is Lys; R is NH_2

Ψ is CH_2-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is D-Arg; Xcc^{15} is Lys; R is NH_2

Ψ is CO-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is D-Arg; Xcc^{15} is Lys; R is OH

Ψ is CH_2-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is D-Arg; Xcc^{15} is Lys; R is OH

Ψ is CO-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is D-Arg; Xcc^{15} is D-Lys; R is NH_2

Ψ is CH_2-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is D-Arg; Xcc^{15} is D-Lys; R is NH_2

Ψ is CO-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is D-Arg; Xcc^{15} is D-Lys; R is OH

Ψ is CH_2-NH; Xaa^4 is Phe(pNO_2); Xbb^{14} is D-Arg; Xcc^{15} is D-Lys; R is OH

Ψ is CO-NH; Xaa^4 is D-Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is Lys; R is NH_2

Ψ is CH_2-NH; Xaa^4 is D-Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is Lys; R is NH_2

XII. Ψ is CO-NH; Xaa^4 is D-Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is Lys; R is OH

Ψ is CH_2-NH; Xaa^4 is D-Phe(pNO_2); Xbb^{14} is Arg; Xcc^{15} is Lys; R is OH

5. Peptide according to Claim 4, selected from the group consisting of:

a)H-Phe-Gly-Gly-(pF)Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Arg-Lys-Asn-Gln-NH_2

b)H-Phe-Ψ(CH_2NH)-Gly-Gly-(pF)Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Arg-Lys-Asn-Gln-NH_2

6. Pharmaceutical composition containing a peptide according to Claim 1, together with pharmaceutically accettable excipients.

7. A method for treating disorders conditions or pathological states in which it is desirable to obtain the activation of the NOP receptors, said method comprising administering an effective amount of a peptide according to Claim 1 to a patient in need of such a treatment.

8. A method according to Claim 7, wherein said disorder condition or pathological state is selected from the group consisting of hypertension, tachycardia, water-retaining diseases, hyponatremia, heart failure, motility dysfunctions of the smooth muscle in the gastrointestinal, respiratory and genitourinary tracts, inflammatory states, peripheral and spinal analgesia, inhibition of cough.

9. A method according to Claim 7, wherein said disorder condition or pathological state is urinary incontinence due to neurogenic bladder and bladder hyperactivity.

10. A method according to Claim 7, wherein said disorder condition or pathological state is cough.

11. A method according to Claim 7, wherein said disorder condition or pathological state is gastrointestinal hypermotility.

12. A method according to Claim 7, wherein said disorder condition or pathological state is hyponatriemiam heart failure and hypertension.

13. A method according to Claim 7, wherein said disorder condition or pathological state is chronic pain.

14. A method according to Claim 7, wherein said patient is a mammalian.

15. A method according to Claim 7, wherein said patient is a human being.